BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

367 related articles for article (PubMed ID: 34358141)

  • 1. Bispecific Antibodies: A Smart Arsenal for Cancer Immunotherapies.
    You G; Won J; Lee Y; Moon D; Park Y; Lee SH; Lee SW
    Vaccines (Basel); 2021 Jul; 9(7):. PubMed ID: 34358141
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bispecific antibodies in cancer immunotherapy.
    Dahlén E; Veitonmäki N; Norlén P
    Ther Adv Vaccines Immunother; 2018 Feb; 6(1):3-17. PubMed ID: 29998217
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bispecific antibodies targeting immunomodulatory checkpoints for cancer therapy.
    Zhang T; Lin Y; Gao Q
    Cancer Biol Med; 2023 Mar; 20(3):181-95. PubMed ID: 36971124
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bispecific antibodies targeting CTLA-4: game-changer troopers in cancer immunotherapy.
    Farhangnia P; Ghomi SM; Akbarpour M; Delbandi AA
    Front Immunol; 2023; 14():1155778. PubMed ID: 37441075
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The enhanced antitumor activity of bispecific antibody targeting PD-1/PD-L1 signaling.
    Li T; Niu M; Zhou J; Wu K; Yi M
    Cell Commun Signal; 2024 Mar; 22(1):179. PubMed ID: 38475778
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anti-PD-L1-Based Bispecific Antibodies Targeting Co-Inhibitory and Co-Stimulatory Molecules for Cancer Immunotherapy.
    Geng Q; Jiao P
    Molecules; 2024 Jan; 29(2):. PubMed ID: 38257366
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development of a mechanism of action-reflective, dual target cell-based reporter bioassay for a bispecific monoclonal antibody targeting human CTLA-4 and PD-1.
    Chen W; Pandey M; Sun H; Rolong A; Cao M; Liu D; Wang J; Zeng L; Hunter A; Lin S
    MAbs; 2021; 13(1):1914359. PubMed ID: 33870864
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Advances in the study of CD47-based bispecific antibody in cancer immunotherapy.
    Zhang B; Li W; Fan D; Tian W; Zhou J; Ji Z; Song Y
    Immunology; 2022 Sep; 167(1):15-27. PubMed ID: 35575882
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bispecific antibodies for treatment of cancer in experimental animal models and man.
    de Leij L ; Molema G; Helfrich W; Kroesen BJ
    Adv Drug Deliv Rev; 1998 Apr; 31(1-2):105-129. PubMed ID: 10837620
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antibody-drug conjugates and bispecific antibodies targeting cancers: applications of click chemistry.
    Hong Y; Nam SM; Moon A
    Arch Pharm Res; 2023 Mar; 46(3):131-148. PubMed ID: 36877356
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bispecific antibodies revolutionizing breast cancer treatment: a comprehensive overview.
    Lan HR; Chen M; Yao SY; Chen JX; Jin KT
    Front Immunol; 2023; 14():1266450. PubMed ID: 38111570
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Challenges and strategies for next-generation bispecific antibody-based antitumor therapeutics.
    Li H; Er Saw P; Song E
    Cell Mol Immunol; 2020 May; 17(5):451-461. PubMed ID: 32313210
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The present and future of bispecific antibodies for cancer therapy.
    Klein C; Brinkmann U; Reichert JM; Kontermann RE
    Nat Rev Drug Discov; 2024 Apr; 23(4):301-319. PubMed ID: 38448606
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Factors Affecting the Cancer Immunotherapeutic Efficacy of T Cell Bispecific Antibodies and Strategies for Improvement.
    Long M; Mims AS; Li Z
    Immunol Invest; 2022 Nov; 51(8):2176-2214. PubMed ID: 36259611
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A review of bispecific antibodies and antibody constructs in oncology and clinical challenges.
    Suurs FV; Lub-de Hooge MN; de Vries EGE; de Groot DJA
    Pharmacol Ther; 2019 Sep; 201():103-119. PubMed ID: 31028837
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Potential Role of CD47-Directed Bispecific Antibodies in Cancer Immunotherapy.
    Yang Y; Yang Z; Yang Y
    Front Immunol; 2021; 12():686031. PubMed ID: 34305918
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of bispecific antibodies vs. immune checkpoint blockade combination therapy in cancer: a real-world comparison.
    Cheng L; Chen L; Shi Y; Gu W; Ding W; Zheng X; Liu Y; Jiang J; Zheng Z
    Mol Cancer; 2024 Apr; 23(1):77. PubMed ID: 38627681
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Simultaneous Inhibition of PD-1 and Stimulation of CD40 Signaling Pathways by Anti-PD-L1/CD40L Bispecific Fusion Protein Synergistically Activate Target and Effector Cells.
    Pandey MS; Wang C; Umlauf S; Lin S
    Int J Mol Sci; 2021 Oct; 22(21):. PubMed ID: 34768776
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bispecific antibodies targeting dual tumor-associated antigens in cancer therapy.
    Huang S; van Duijnhoven SMJ; Sijts AJAM; van Elsas A
    J Cancer Res Clin Oncol; 2020 Dec; 146(12):3111-3122. PubMed ID: 32989604
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bispecific antibody targeting TGF-β and PD-L1 for synergistic cancer immunotherapy.
    Li T; Wang X; Niu M; Wang M; Zhou J; Wu K; Yi M
    Front Immunol; 2023; 14():1196970. PubMed ID: 37520520
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.